NVST
Price
$22.00
Change
+$0.13 (+0.59%)
Updated
Dec 24 closing price
Capitalization
3.62B
47 days until earnings call
Intraday BUY SELL Signals
STXS
Price
$2.43
Change
-$0.02 (-0.82%)
Updated
Dec 24 closing price
Capitalization
226.78M
63 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NVST vs STXS

Header iconNVST vs STXS Comparison
Open Charts NVST vs STXSBanner chart's image
Envista Holdings
Price$22.00
Change+$0.13 (+0.59%)
Volume$589.73K
Capitalization3.62B
Stereotaxis
Price$2.43
Change-$0.02 (-0.82%)
Volume$269.15K
Capitalization226.78M
NVST vs STXS Comparison Chart in %
NVST
Daily Signal:
Gain/Loss:
STXS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NVST vs. STXS commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVST is a Buy and STXS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (NVST: $22.00 vs. STXS: $2.43)
Brand notoriety: NVST and STXS are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: NVST: 27% vs. STXS: 50%
Market capitalization -- NVST: $3.62B vs. STXS: $226.78M
NVST [@Pharmaceuticals: Other] is valued at $3.62B. STXS’s [@Pharmaceuticals: Other] market capitalization is $226.78M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $204.6B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $11.61B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVST’s FA Score shows that 1 FA rating(s) are green whileSTXS’s FA Score has 0 green FA rating(s).

  • NVST’s FA Score: 1 green, 4 red.
  • STXS’s FA Score: 0 green, 5 red.
According to our system of comparison, NVST is a better buy in the long-term than STXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVST’s TA Score shows that 5 TA indicator(s) are bullish while STXS’s TA Score has 5 bullish TA indicator(s).

  • NVST’s TA Score: 5 bullish, 5 bearish.
  • STXS’s TA Score: 5 bullish, 1 bearish.
According to our system of comparison, STXS is a better buy in the short-term than NVST.

Price Growth

NVST (@Pharmaceuticals: Other) experienced а +0.69% price change this week, while STXS (@Pharmaceuticals: Other) price change was +4.74% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.63%. For the same industry, the average monthly price growth was -0.63%, and the average quarterly price growth was +1.00%.

Reported Earning Dates

NVST is expected to report earnings on Feb 11, 2026.

STXS is expected to report earnings on Feb 27, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (-0.63% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVST($3.62B) has a higher market cap than STXS($227M). NVST YTD gains are higher at: 14.049 vs. STXS (6.579). NVST has higher annual earnings (EBITDA): 341M vs. STXS (-22.57M). NVST has more cash in the bank: 1.13B vs. STXS (10.5M). STXS has less debt than NVST: STXS (5.58M) vs NVST (1.6B). NVST has higher revenues than STXS: NVST (2.62B) vs STXS (30.1M).
NVSTSTXSNVST / STXS
Capitalization3.62B227M1,593%
EBITDA341M-22.57M-1,511%
Gain YTD14.0496.579214%
P/E Ratio244.44N/A-
Revenue2.62B30.1M8,711%
Total Cash1.13B10.5M10,800%
Total Debt1.6B5.58M28,694%
FUNDAMENTALS RATINGS
NVST vs STXS: Fundamental Ratings
NVST
STXS
OUTLOOK RATING
1..100
2832
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
90100
PRICE GROWTH RATING
1..100
4659
P/E GROWTH RATING
1..100
457
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVST's Valuation (86) in the null industry is in the same range as STXS (99) in the Medical Specialties industry. This means that NVST’s stock grew similarly to STXS’s over the last 12 months.

NVST's Profit vs Risk Rating (100) in the null industry is in the same range as STXS (100) in the Medical Specialties industry. This means that NVST’s stock grew similarly to STXS’s over the last 12 months.

NVST's SMR Rating (90) in the null industry is in the same range as STXS (100) in the Medical Specialties industry. This means that NVST’s stock grew similarly to STXS’s over the last 12 months.

NVST's Price Growth Rating (46) in the null industry is in the same range as STXS (59) in the Medical Specialties industry. This means that NVST’s stock grew similarly to STXS’s over the last 12 months.

NVST's P/E Growth Rating (4) in the null industry is somewhat better than the same rating for STXS (57) in the Medical Specialties industry. This means that NVST’s stock grew somewhat faster than STXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVSTSTXS
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
69%
Bullish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
65%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 5 days ago
62%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
70%
Bearish Trend 12 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
76%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 3 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
NVST
Daily Signal:
Gain/Loss:
STXS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JVTIX89.220.26
+0.29%
Janus Henderson Venture I
MLNIX27.400.07
+0.26%
Morgan Stanley Instl Glbl Concntr I
FAGCX245.460.48
+0.20%
Fidelity Advisor Growth Opps I
KLGCX46.050.09
+0.20%
NYLI WMC Growth Class C
ETAEX14.79N/A
N/A
Eventide Exponential Technologies A

NVST and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVST has been closely correlated with XRAY. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVST jumps, then XRAY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVST
1D Price
Change %
NVST100%
+0.59%
XRAY - NVST
69%
Closely correlated
+1.26%
ALGN - NVST
57%
Loosely correlated
+0.69%
BIO - NVST
57%
Loosely correlated
+0.24%
A - NVST
55%
Loosely correlated
-0.03%
SOLV - NVST
54%
Loosely correlated
-0.46%
More

STXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, STXS has been loosely correlated with SMTI. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then SMTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STXS
1D Price
Change %
STXS100%
-0.82%
SMTI - STXS
43%
Loosely correlated
+0.04%
NVST - STXS
37%
Loosely correlated
+0.59%
TWST - STXS
36%
Loosely correlated
-0.77%
CERS - STXS
35%
Loosely correlated
N/A
UTMD - STXS
35%
Loosely correlated
-1.14%
More